Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Otolaryngology and Head & Neck Surgery
Published in: Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019

01-10-2019 | Original Article

Xanthelasma Palpebrarum: More than Meets the Eye

Authors: Shailesh Khode, Soon Heng Terry Tan, En-Pei Amanda Tan, Sandeep Uppal

Published in: Indian Journal of Otolaryngology and Head & Neck Surgery | Special Issue 1/2019

Login to get access

Abstract

Xanthelasma palpebrarum (XP) is the most common form of cutaneous xanthomata, and is important aesthetically, because of its close relation to the eyes, as well as medically for its association with cardiovascular disease (CVD). To provide avant-garde review discussing the various aspects of XP, including its aetio-pathogenesis and various treatment modalities. A structured Pubmed and Medline were searched for relevant articles. The finding of recent research has strongly espoused the link between XP and CVD, and mechanisms have been suggested for its formation. The new technologies have led to a multitude of treatment options for XP. XP is a multi-faceted entity; other than simple treatment of the cosmetic aspect of the disease, one must be cognizant of its cardiovascular implications.
Literature
1.
Bergman R (1994) The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 30(2):236–242PubMed
2.
Domonkoa AN, Arnold HL Jr., Odom RB (1982) Andrews’ diseases of the skin: clinical dermatology, 7th edn. WB Saunders, Philadelphia, pp 658–660
3.
Jónsson A, Sigfŭsson N (1976) Letter: significance of xanthelasma palpebrarum in the normal population. Lancet 1(7955):372PubMed
4.
Dequeker J, Muls E, Leenders K (2004) Xanthelasma and lipoma in Leonardo da Vinci’s Mona Lisa. Isr Med Assoc J 6(8):505–506PubMed
5.
6.
Sarkany RPE, Breathnach SM, Seymour CA et al (2004) Metabolic and nutritional diseases. In: Burns T, Breathnach S, Cox N et al (eds) Rook’s textbook of dermatology, vol 7. Blackwell, Oxford, p 57.1e57.124
7.
Matsumoto M, Kunimitsu S, Wada K, Ikeda M, Keyama A, Kodama H (2007) Mast cell distribution, activation, and phenotype in xanthoma. J Am Acad Dermatol 56(6):1006–1012PubMed
8.
Parker F, Odland GF (1968) Experimental xanthoma. A correlative biochemical, histologic, histochemical, and electron microscopic study. Am J Pathol 53(4):537–565PubMedPubMedCentral
9.
Parker F, Peterson N, Odland GF (1966) A comparison of cholesterol-ester fatty acid patterns in the blood and in evolving xanthoma and atheroma during cholesterol-feeding of rabbits. J Invest Dermatol 47(3):253–259PubMed
10.
Watanabe A, Yoshimura A, Wakasugi T et al (1981) Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 38:283–290PubMed
11.
Ribera M, Pinto X, Argimon JM et al (1995) Lipid metabolism and apolipoprotein-E phenotypes in patients with xanthelasma. Am J Med 99:485–490PubMed
12.
Gómez JA, Gónzalez MJ, de Moragas JM, Serrat J, Gónzalez-Sastre F, Pérez M (1988) Apolipoprotein E phenotypes, lipoprotein composition, and xanthelasmas. Arch Dermatol 124(8):1230–1234PubMed
13.
Montgomery H, Osterberg A (1938) Xanthomatosis: correlation of clinical, histopathologic, and chemical studies of cutaneous xanthoma. Arch Dermatol 37:373–401
14.
Vacca JB, Knight WA, Broun GO (1959) Clinical observations regarding xanthelasma. Ann Intern Med 51:1019–1031PubMed
15.
Epstein NN, Rosenmann RH, Gofman JW (1952) Serum lipoproteins and cholesterol metabolism in xanthelasma. Arch Dermatol 65:70–81
16.
Pedace JF, Winkelmann RK (1965) Xanthelasma palpebrarum. J Am Med Assoc 193:893–894
17.
Bergman R (1998) Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 37(5):343–345PubMed
18.
Bergman R, Kasif Y, Aviram M, Maor I, Ullman Y, Gdal-On M, Friedman-Birnbaum R (1996) Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 76(2):107–110PubMed
19.
Douste-Blazy P, Marcel YL, Cohen L, Giroux JM, Davignon J (1982) Increased Frequency of Apo E-ND phenotype and hyperapobeta-lipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids. Ann Intern Med 96(2):164–169PubMed
20.
Greenland P, Abrams J, Aurigemma GP et al (2000) Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden—Writing Group III. Circulation 101:E16e22
21.
Noël B (2007) Premature atherosclerosis in patients with xanthelasma. J Eur Acad Dermatol Venereol 21(9):1244–1248PubMed
22.
Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV (1038) Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J 2012(88):198–204
23.
Akyuz AR, Turan T, Erkus ME, Gurbak KS et al (2016) Xanthelasma palpebrarum associated with increased cardio-ankle vascular index in asymptomatic subjects. Wien Klin Wochenschr 128(suppl 8):610–613PubMed
24.
Bhat J, Smith AG (2003) Xanthelasma palpebrarum following allergic contact dermatitis from para-phenylenediamine in a black eyelash-tinting product. Contact Dermat 49(6):311
25.
Platsidaki E, Kouris A, Agiasofitou E, Antoniou C, Kontochristopoulos G (2016) Periorbital hyperpigmentation in patients with xanthelasma palpebrarum :an interesting observation. J Clin Aesthet Dermatol 9(4):52–54PubMedPubMedCentral
26.
D’Acunto C, Pazzaglia M, Raone B, Misciali C, Badiali L, Neri I, Patrizi A (2013) Xanthelasma palpebrarum: a new adverse reaction to intradermal fillers? Br J Dermatol 168(2):437–439PubMed
27.
Başterzi Y, Sari A (2006) Xanthelasma palpebrarum after septorhinoplasty. Aesthetic Plast Surg 30(4):492–493PubMed
28.
Scott PJ, Winterbourn CC (1967) Low-density lipoprotein accumulation in actively growing xanthomas. J Atheroscler Res 7(2):207–223PubMed
29.
Seike M, Ikeda M, Matsumoto M, Hamada R, Takeya M, Kodama H (2006) Hyaluronan forms complexes with low density lipoprotein while also inducing foam cell infiltration in the dermis. J Dermatol Sci 41(3):197–204PubMed
30.
31.
Karsai S, Czarnecka A, Raulin C (2010) Treatment of xanthelasma palpebrarum using a pulsed dye laser: a prospective clinical trial in 38 cases. Dermatol Surg 36(5):610–617PubMed
32.
Parkes ML, Waller TS (1984) Xanthelasma palpebrarum. Laryngoscope 94(9):1238–1240PubMed
33.
Lee HY, Jin US, Minn KW, Park Y-O (2013) Outcomes of surgical management of xanthelasma palpebrarum. Arch Plast Surg 40:380–386PubMedPubMedCentral
34.
Kose R (2013) Treatment of large xanthelasma palpebrarums with full-thickness skin grafts obtained by blepharoplasty. J Cutan Med Surg 17(3):197–200PubMed
35.
Roberts HL (1926) The Chloroacetic acids: a biochemical study. Br J Dermatol 38:323–391
36.
Haygood LJ, Bennett JD, Brodell RT (1998) Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg 24(9):1027–1031PubMed
37.
Cannon PS, Ajit R, Leatherbarrow B (2010) Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. Clin Exp Dermatol 35(8):845–848PubMed
38.
Haque MU, Ramesh V (2006) Evaluation of three different strengths of trichloroacetic acid in xanthelasma palpebrarum. J Dermatol Treat 17(1):48–50
39.
Nahas TR, Marques JC, Nicoletti A, Cunha M, Nishiwaki-Dantas MC, Filho JV (2009) Treatment of eyelid xanthelasma with 70% trichloroacetic acid. Ophthalmic Plast Reconstr Surg 25(4):280–283PubMed
40.
Dincer D, Koc E, Erbil AH, Kose O (2010) Effectiveness of low-voltage radiofrequency in the treatment of xanthelasma palpebrarum: a pilot study of 15 cases. Dermatol Surg 36(12):1973–1978PubMed
41.
Dawber R, Colver G, Jackson A, Pringle F (1992) Cutaneous cryosurgery. Principles and Clinical practice. Martin Dunitz, London
42.
Kuflik EG, Gage AA (1990) Cryosurgical treatment of skin cancer. Igaku-Shoin, Newyork
43.
Sheperd J, Dawber RP (1982) The historical and scientific basis of cryosurgery. Clin Exp Dermatol 7:321–328
44.
Dewan SP, Kaur A, Gupta RK (1995) Effectiveness of cryosurgery in xanthelasma palpebrarum. Indian J Dermatol Venereol Leprol 61(1):4–7PubMed
45.
Labandeira J, Vázquez-Osorio I, Figueroa-Silva O, Pereiro M Jr, Toribio J (2015) Tolerability and effectiveness of liquid nitrogen spray cryotherapy with very short freeze times in the treatment of xanthelasma palpebrarum. Dermatol Ther 28(6):346–350PubMed
46.
Delgado Navarro C, Lanuza García A, Llorca Cardeñosa A, Bañón-Navarro R, Corchero MG (2013) Application of laser CO2 for the treatment of xanthelasma palpebrarum. Arch Soc Esp Oftalmol 88:320–322PubMed
47.
Raulin C, Schoenermark MP, Werner S, Greve B (1999) Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med 24(2):122–127PubMed
48.
Pathania V, Chatterjee M (2015) Ultrapulse carbon dioxide laser ablation of xanthelasma palpebrarum: a case series. J Cutan Aesthet Surg 8(1):46–49PubMedPubMedCentral
49.
Saif MYS (2007) Xanthelasma palpebrarum treatment by CO2 laser. Bull Ophthalmol Soc Egypt 100:791–794
50.
Esmat SM, Elramly AZ, Abdel Halim DM, Gawdat HI, Taha HI (2014) Fractional CO2 laser is an effective therapeutic modality of xanthelasma palpebrarum: a randomized clinical trial. Dermatol Surg 40(20):1349–1355PubMed
51.
Borelli C, Kaudewitz P (2001) Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med 29(3):260–264PubMed
52.
Mannino G, Papale A, De Bella F, Mollo R (2001) Use of Erbium:YAG laser in the treatment of palpepral xanthelasmas. Opthalmic Surg Lasers 32:129–133
53.
Kaufmann R, Hibst R (1996) Pulsed Erbium-YAG laser ablation in cutaneous surgery. Lasers Surg Med 19:324–330PubMed
54.
Drnovsek-Olup B, Vedlin B (1997) Use of Erbium:YAG laser for benign skin disorders. Lasers Surg Ned 21:13–19
55.
Levy JL, Trelles MA (2003) New operative technique for treatment of xanthelasma palpebrarum: laser-inverted resurfacing: preliminary report. Ann Plast Surg 50(4):339–343PubMed
56.
Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS (1989) Selective photothermolysis of cutaneous pigmentation by Q-switched Nd: YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 93(1):28–32PubMed
57.
Fusade T (2008) Treatment of xanthelasma palpebrarum by 1064-nm Q-switched Nd: YAG laser: a study of 11 cases. Br J Dermatol 158(1):84–87PubMed
58.
Karsai S, Schmitt L, Raulin C (2009) Is Q-switched neodymium-doped yttrium aluminium garnet laser an effective approach to treat xanthelasma palpebrarum? Results from a clinical study of 76 cases. Dermatol Surg 35(12):1962–1969PubMed
59.
Marini L (2013) 1064 nm Q-switched photo-acoustic laser ablation of xanthelasma palpebrarum. J Laser Health Acad 1:48–51
60.
Berger C, Kopera D (2005) KTP laser coagulation for xanthelasma palpebrarum. J Dtsch Dermatol 3(10):775–779
61.
Greijmans E, Luiting-Welkenhuyzen H, Luijks H, Bovenschen HJ (2016) Continuous wave potassium titanyl phosphate laser treatment is safe and effective for xanthelasma palpebrarum. Dermatol Surg 42(7):860–866PubMed
62.
Schönermark MP, Raulin C (1996) Treatment of xanthelasma palpebrarum with the pulsed dye laser. Lasers Surg Med 19(3):336–339PubMed
63.
Astner S (2009) Clinical applicability of a 1 450 nm diode laser as adjunctive treatment for refractory acne. G Ital Dermatol Venereol 144(6):629–638PubMed
64.
Friedman PM, Jih MH, Kimyai-Asadi A, Goldberg LH (2004) Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. Dermatol Surg 30(2 Pt 1):147–151PubMed
65.
No D, McClaren M, Chotzen V, Kilmer SL (2004) Sebaceous hyperplasia treated with a 1450-nm diode laser. Dermatol Surg 30(3):382–384PubMed
66.
Chua SH, Ang P, Khoo LS, Goh CL (2004) Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg 30(10):1287–1291PubMed
67.
Park EJ, Youn SH, Cho EB, Lee GS, Hann SK, Kim KH, Kim KJ (2011) Xanthelasma palpebrarum treatment with a 1450-nm-diode laser. Dermatol Surg 37(6):791–796PubMed
68.
Shields CL, Mashayekhi A, Shields JA (2005) Disappearance of eyelid xanthelasma following oral simvastatin (Zocor). Br J Ophthalmol 89:639–645PubMedPubMedCentral
69.
Wang H, Shi Y, Guan H, Liu C, Zhang W et al (2016) Treatment of xanthelasma palpebrarum with intralesional pingyangmycin. Dermatol Surg 42(3):368–376PubMed
70.
Mourad B, Elgarhy LH, Ellakkawy HA, Elmahdy N (2015) Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum. J CosmetDermatol 14(3):209–215
71.
Goel K, Sardana K, Garg VK (2015) A prospective study comparing ultrapulse CO2 laser and trichloroacetic acid in treatment of Xanthelasmapalpebrarum. J Cosmet Dermatol 14(2):130–139PubMed
72.
Abdelkader M, Alashry SE (2015) Argon laser versus erbium:YAG laser in the treatment of xanthelasma palpebrarum. Saudi J Ophthalmol 29(2):116–120PubMed
73.
Güngör S, Canat D, Gökdemir G (2014) Erbium:YAG laser ablation versus 70% trichloroacetıc acid application in the treatment of xanthelasma palpebrarum. J Dermatol Treat 25(4):290–293
Metadata
Title
Xanthelasma Palpebrarum: More than Meets the Eye
Authors
Shailesh Khode
Soon Heng Terry Tan
En-Pei Amanda Tan
Sandeep Uppal
Publication date
01-10-2019
Publisher
Springer India
Published in
Indian Journal of Otolaryngology and Head & Neck Surgery / Issue Special Issue 1/2019
Print ISSN: 2231-3796
Electronic ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-018-1345-0

Other articles of this Special Issue 1/2019

Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019 Go to the issue

Original Article

Factors Affecting Postoperative Complications After Reconstructive Surgery in Oral Carcinoma Patients: A Prospective Study of 100 Patients

Original Article

Design and Implementation of Competency Based Postgraduate Medical Education in Otorhinolaryngology: The Pilot Experience in India

Original Article

Airway Management and Bronchoscopic Treatment of Subglottic and Tracheal Stenosis Using Holmium Laser with Balloon Dilatation

Original Article

Histological and Histochemical Observations on Mast Cell and Glands in Chronic Tonsillitis

Clinical Report

Salmonella Thyroid Abscess Treated by Serial Aspiration: Case Report and Literature Review

Clinical Report

Transverse Cervical Artery Pseudoaneurysm: An Unusual Delayed Complication of Radical Neck Dissection